Year: 2021

Phase 1b/2 Study Evaluating DAY101 in Combination with Pimasertib, Day One’s MEK Inhibitor, Expected to Begin in First Quarter of 2022SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating DAY101 as a monotherapy in patients with RAF-altered solid tumors. DAY101 is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway. “DAY101 has demonstrated encouraging anti-tumor activity as a monotherapy in patient populations where MAPK...

Fourth Quarter and Fiscal Year HighlightsStrong bookings of $590M in FY21 – increases backlog to approximately $2 billion Momentum for new products leads to orders representing nearly 20% of total bookings Won first major customer in the building mobility market for the connected elevator of the future VinFast, Vietnam’s first domestic car company and a leader in electric vehicle innovation worldwide, selected Cerence to power conversational AI across its lineup of smart EVs Cerence Pay receives coveted Automotive News PACE Award, the industry benchmark for innovation Quarterly revenue grew 7.5% year over year, full year revenue grew 17% Met or exceeded nearly all profitability metrics for the quarter and fiscal yearBURLINGTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion,...

CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company’s Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. “Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positions at global biotechnology and life sciences companies,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis....

Pfizer-BioNTech vaccine demonstrated 100% efficacy against COVID-19 in longer-term analysis, with no serious safety concerns identified Data will support planned submissions for full regulatory approval of the vaccine in this age group in the U.S. and worldwide NEW YORK and MAINZ, GERMANY, November 22, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age. The updated findings from the companies’ pivotal Phase 3 trial show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the second dose. The adverse event profile was generally consistent with other clinical...

BOSTON HEIGHTS, Ohio, Nov. 22, 2021 (GLOBE NEWSWIRE) — Arhaus (NASDAQ: ARHS), a rapidly growing lifestyle brand and omni-channel retailer of premium home furnishings, will release its third quarter 2021 financial results before market open on Thursday, December 9, 2021. The Company will host a conference call at 8:30 am Eastern Time the same day to review financial and operational results and answer questions from the investment community. Investors will be able to access the press release, conference call webcast, and supplementary slides on the Company’s website, http://ir.arhaus.com. Details for the conference call follow:Date:        December 9, 2021Time:        8:30 a.m. Eastern Time To listen via the internet:The call will be webcast on the Investor Relations section of the Company’s website, http://ir.arhaus.com. To listen...

TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) — Red Pine Exploration Inc. (TSX–V: RPX, OTCQB: RDEXF) (the “Company” or “Red Pine”) announces that the Company’s common shares are now trading on the OTCQB Marketplace, a U.S. trading platform operated by the OTC Markets Group Inc. The Company’s OTC stock symbol remains as “RDEXF” following the uplisting from the OTC Pink Sheets. Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com. “With the uplisting to the OTCQB, Red Pine validates its long-term strategy to expand accessibility of the Company to a broader audience” said Quentin Yarie, CEO and President of Red Pine Exploration. “Our U.S. investor base is an important group of shareholders, and I am pleased to be increasing our exposure to one of the largest...

LA JOLLA, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, presented new data regarding MN-166 (ibudilast) from a glioblastoma animal model study at the 26th Annual Meeting of the Society for Neuro-Oncology (SNO) held November 18 – 21, 2021 in Boston. This study was a collaborative effort between MediciNova and Dr. Lathia and Dr....

WALTHAM, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Jill Andersen has been appointed as chief legal officer, bringing over 20 years of legal, compliance and leadership experience in the pharmaceutical industry, government and private practice. In addition, Redonda Miller, M.D., MBA, president of The Johns Hopkins Hospital, and Ellen Marram, an experienced corporate director and board leader, and the former CEO of several consumer product companies, have joined Adagio’s board of directors. “We are thrilled to expand our executive team and welcome Jill as our chief legal officer,” said Tillman...